证券日报网讯 8月18日晚间，赛分科技发布公告称，2025年半年度公司实现营业收入182，632，897.75 元，同比增长19.76%；归属于上市公司股东的净利润为53，659，195.85元，同比增长40.91%。 （文章来源：证券日报） ...

Core Insights - The biopharmaceutical industry is accelerating commercialization processes, significantly boosting the demand for chromatography materials due to multiple innovative drug projects entering production stages [1] - The company, Saifen Technology, has achieved dual breakthroughs in performance and technical strength, with its industrial purification business being the main growth driver [2] - The company has made significant advancements in core technologies, enhancing its product offerings and establishing itself as an industry benchmark [4] Industry Overview - The demand for chromatography consumables is surging, driven by the expansion of GLP-1 drugs and recombinant proteins, creating vast growth opportunities for Saifen Technology [1] - The industrial purification sector has shown remarkable performance, with sales revenue reaching 120 million yuan, a year-on-year increase of 28.59%, accounting for 65.97% of total revenue [2] - The company has completed 87 clinical phase III and commercialization projects for imported filler replacements, with a focus on antibodies, GLP-1, and recombinant proteins [6] Company Performance - In the first half of 2025, Saifen Technology reported a revenue of 183 million yuan, a year-on-year growth of 19.76%, with a gross margin of 70.60% [5] - The net profit attributable to the parent company reached 53.66 million yuan, up 40.91% year-on-year, with a net profit excluding non-recurring items of 46.50 million yuan, reflecting a growth of 22.08% [5] - The company has expanded its customer base and increased sales to significant clients, with sales exceeding 10 million yuan contributing to 86.22% of the industrial purification revenue [2] Technological Advancements - Saifen Technology has upgraded its core technology platforms, launching new industrial purification products, including high-performance affinity and cation exchange fillers [4] - The company has achieved precise control over microsphere synthesis and developed surface modification techniques to enhance product performance [4] - The introduction of a new generation of size exclusion chromatography columns supports global business expansion and solidifies the company's position among top international chromatography firms [3] Future Outlook - Saifen Technology plans to increase R&D investment, deepen chromatography technology, and continue launching innovative products to enhance performance and quality [6] - The company aims to accelerate the domestic substitution process and strengthen collaborations with domestic pharmaceutical companies to expand market share [6] - The completion of the second phase of the Yangzhou project will enable an annual production capacity of over 200,000 liters of chromatography media, supporting domestic substitution and pharmaceutical growth demands [6]

证券日报网讯 8月18日晚间，赛分科技发布公告称，公司于2025年8月16日召开第二届董事会2025年第 四次会议，审议通过了《关于补选非独立董事的议案》《关于调整董事会审计委员会委员的议案》。公 司董事会同意提名倪灏（HAONI）先生为公司第二届董事会非独立董事候选人，任期自公司股东会审 议通过之日起至第二届董事会届满之日止。为完善公司治理结构，保障公司董事会审计委员会规范运 作，公司董事会拟对第二届董事会审计委员会部分成员进行调整，即公司董事长、总经理黄学英先生不 再担任公司第二届董事会审计委员会委员，由公司独立董事徐锋先生担任审计委员会委员，与彭淑贞女 士、梁永伟先生共同组成公司第二届董事会审计委员会，任期自本次董事会审议通过之日起至公司第二 届董事会任期届满之日止。 （编辑 任世碧） ...

（文章来源：证券日报） 证券日报网讯 8月18日晚间，赛分科技发布公告称，公司第二届董事会2025年第四次会议审议通过了 《关于公司及摘要的议案》等多项议案。 ...

（文章来源：证券日报） 证券日报网讯 8月18日晚间，赛分科技发布公告称，公司将于2025年9月3日召开2025年第一次临时股东 会。本次股东会将审议《关于补选非独立董事的议案》等多项议案。 ...

（文章来源：证券日报） 证券日报网讯 8月18日晚间，赛分科技发布公告称，公司定于2025年8月26日（星期二）15：00-16：00 在"价值在线"举办公司2025年半年度业绩说明会。 ...

证券日报网讯 8月18日晚间，赛分科技发布关于2025年半年度利润分配方案的公告称，公司拟向全体股 东每股派发现金红利0.026元（含税），不进行资本公积转增股本，不送红股。截至2025年6月30日，公 司总股本416，464，084股，以此计算合计拟派发现金红利10，828，066.18元（含税），占2025年半年 度归属于上市公司股东净利润的20.18%。 （文章来源：证券日报） ...

证券时报·数据宝统计显示，公司今日公布了半年报，共实现营业收入1.83亿元，同比增长19.76%，实 现净利润5365.92万元，同比增长40.91%，基本每股收益为0.1315元，加权平均净资产收益率为4.28%。 8月18日赛分科技发布2025半年度分配预案，拟10派0.26元（含税），预计派现金额合计为1082.81万 元。派现额占净利润比例为20.18%，这是公司上市以来，累计第2次派现。 公司上市以来历次分配方案一览 | 日期 | 分配方案 | 派现金额合计（亿元） | 股息率（%） | | --- | --- | --- | --- | | 2025.06.30 | 10派0.26元（含税） | 0.11 | 0.15 | | 2024.12.31 | 10派0.41元（含税） | 0.17 | | 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 资金面上看，该股今日主力资金净流出410.68万元，近5日主力资金净流出1207.63万元。 （文章来源：证券时报网） 两融数据显示，该股最新融资余额为4254.34万元，近5日减少1036.37万元，降幅为19.59%。 业 按申万行业统 ...

赛分科技8月18日披露半年报，公司上半年实现营业收入1.83亿元，同比增长19.76%；归属于上市公司 股东的净利润5365.92万元，同比增长40.91%；基本每股收益0.1315元。 ...

Core Viewpoint - Suzhou Sepax Technologies Co., Ltd. reported a significant increase in revenue and net profit for the first half of 2025, indicating strong business growth and operational improvements. Financial Performance - The company achieved operating revenue of RMB 182.63 million, a year-on-year increase of 19.76% compared to RMB 152.49 million in the same period last year [4]. - Total profit reached RMB 62.88 million, up 34.93% from RMB 46.60 million [4]. - Net profit attributable to shareholders was RMB 53.66 million, reflecting a 40.91% increase from RMB 38.08 million [4]. - The net cash flow from operating activities was RMB 35.72 million, a 36.32% increase from RMB 26.20 million [4]. - The company's net assets increased to RMB 1.29 billion, up 18.68% from the previous year [4]. Dividend Distribution - The company plans to distribute a cash dividend of RMB 0.026 per share, totaling RMB 10.83 million, which represents 20.18% of the net profit attributable to shareholders for the first half of 2025 [4]. Industry Overview - The chromatography technology market is experiencing growth, with the global chromatography media market expected to reach USD 8.2 billion in 2025, growing at a rate of 9.76% from 2025 to 2026 [16][17]. - The biopharmaceutical sector is the primary application area for chromatography media, with increasing demand driven by the expansion of antibody, vaccine, and recombinant protein markets [16]. - The Chinese chromatography media market is projected to reach RMB 16.7 billion in 2025, with a growth rate of 22.22% from 2025 to 2026 [19]. Chromatography Technology Applications - Chromatography technology is crucial in the pharmaceutical industry, covering the entire drug development process from research and development to clinical trials and production [10][11]. - Analytical chromatography is widely used for drug analysis and quality control, providing essential data for drug development and ensuring safety and efficacy [10][12]. - Industrial purification processes are vital for producing high-purity pharmaceutical products, with chromatography being a core component of these processes [10][14].